Fine Needle Aspiration and Biopsy in the Management of Ovarian Cancer Including Potential Pitfalls
Michael Deavers, MD
Ovarian carcinoma is the most common cause of death of patients with gynecologic cancer. These neoplasms are often high grade and approximately 75% are diagnosed at advanced stage with peritoneal involvement (stage III) or distant spread (stage IV). Currently, many patients receive neoadjuvant chemotherapy (NACT) prior to definitive surgery. The goal of NACT is to reduce morbidity and mortality and to increase the likelihood of optimal debulking. Many of these patients undergo fine needle aspiration biopsy (FNAB) of omental or pelvic tumors to determine the histologic type and grade of malignancy, and to distinguish gynecologic malignancies from other tumors. An accurate diagnosis on FNAB is critical so that the clinician can determine the role of NACT for the patient. Reaching an accurate diagnosis involves several steps, including assessment of adequacy (so that sufficient material is available for interpretation and IHC), work-up of the case, and interpretation. This conference will cover all of these steps and will highlight potential pitfalls. A case presentation format will be used to cover the most common diagnoses, difficult diagnoses and unusual cases.
This educational activity is designed for pathologists, cytopathologists, cytotechnologists, students and other members of the cytopathology community.
Evaluate the use of FNAB for the interpretation of neoplasms that present as omental/pelvic masse
Understand the role of immunohistochemical stains on cell block and/or on corresponding core biopsies
Correlation of cytologic/histologic and immunohistochemical features in the cytology sample, tissue biopsy, and final surgical resection
Current ACCME guidelines state that participants in CME activities should be made aware of any affiliation or financial interest that may affect the speaker’s presentation(s). Therefore, it is the policy of the ASC to insure balance, independence, objectivity, and scientific rigor in all its educational programs. All planning individuals participating in any ASC Educational Activity are expected to disclose to the program audience any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the continuing education program. Click here for a complete list.
Michael Deavers, MD
Donna M. Coffey, MD
The presenter has no conflicts of interest or financial relationships to disclose.
ACCREDITATION AND DESIGNATION STATEMENTS
Continuing Medical Education (CME) Statement
The American Society of Cytopathology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The American Society of Cytopathology designates this enduring educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
American Board of Pathology Maintenance of Certification (MOC)
This product can help fulfill the CME requirements and Self-Assessment Modules (SAMs) mandated by the American Board of Pathology Maintenance of Certification (MOC) process. Earn up to 2.0 SAM Credit Hours.
Continuing Medical Laboratory Education (CMLE)
The ASC designates this activity for a maximum of 2.0 Continuing Medical Laboratory Education (CMLE) credit hours for non-physicians. The CMLE credit hours meet the continuing education requirements for the ASCP Board of Registry Certification Maintenance Program. Participants should claim only the credit commensurate with the extent of their participation in the activity.
Cytotechnologists with Licenses in Florida and California
This program is approved for 2 continuing education credits in the State of Florida and 1 in the State of California. The credit on each link is good for three years from the live presentation date.
- 2.00 AMA PRA Category 1 Credit™
- 1.00 California Credits
- 2.00 CMLE
- 2.00 Florida Credits
- 2.00 MOC II
- 2.00 Participant